Company Filing History:
Years Active: 2006-2013
Title: Gallia Levy: Innovator in ADAMTS Protease Research
Introduction
Gallia Levy is a prominent inventor based in Ann Arbor, MI (US). She has made significant contributions to the field of biochemistry, particularly in the study of disintegrins and metalloproteinases. With a total of 5 patents, her work focuses on the development of novel therapeutic methods and compounds.
Latest Patents
Levy's latest patents revolve around the disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS). One of her notable inventions pertains to a novel ADAMTS13 protease and the nucleic acids encoding these proteases. This invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms, including fragments that possess altered characteristics relative to the wild-type ADAMTS13. Additionally, her patents detail methods for using ADAMTS13 in the treatment of Thrombotic Thrombocytopenic Purpura (TTP), screening for the presence of TTP, and developing anticoagulant drugs based on ADAMTS13.
Career Highlights
Gallia Levy is affiliated with the University of Michigan, where she conducts her research and innovation. Her work has garnered attention for its potential impact on medical treatments and drug development.
Collaborations
Levy has collaborated with notable researchers in her field, including David Ginsburg and Han-Mou Tsai. These collaborations have further advanced her research and contributed to the scientific community's understanding of ADAMTS proteases.
Conclusion
Gallia Levy's innovative work in the field of biochemistry, particularly regarding ADAMTS proteases, showcases her dedication to advancing medical science. Her contributions have the potential to lead to significant advancements in treatment methodologies.